

Site of Service Policy

Date of Origin: 1/1/2019

Updated: 3/26/20, 6/30/20, 11/2/20

I. Background

The Site of Service program, effective January 1, 2019, directs members to the most cost-effective, clinically-appropriate location to receive their infusion(s) of select specialty medications as listed in this policy.

II. Scope

A. Applicable to Commercial and Individual Family/Business membership

1. New utilizers of these medications on or after January 1, 2019 will be subject to the program requirements.
2. Members currently using these medications will be subject to the program requirements upon prior authorization renewal on or after January 1, 2019.

III. Program Requirements

A. The Site of Service program requirements will be administered as part of the existing prior authorization program.

1. To submit a prior authorization request, visit <https://ih.magellanrx.com> and select "Providers and Physicians."
2. If this is your first time requesting a prior authorization through the Magellan Rx self-service portal, visit <https://ih.magellanrx.com> and select "New Access Request-Provider" on the right side of the home page.
3. All drugs in the Site of Service program require prior authorization.

B. Requests for select specialty drugs as listed in section IV to be administered in a hospital outpatient setting will be directed to a preferred alternative site of care, such as a home infusion provider or a physician office. Infusions for these medications are excluded from payment when administered in a hospital outpatient infusion center.

C. To prevent a delay in care and allow adequate transition time for Medica members to an alternate infusion site, Site of Service program requirements will be waived for 60-90 days, depending upon the specific drug, after prior authorization approval so that members can transition to a different infusion site.

IV. Drugs in Scope

- A. Select infused specialty medications included in the Site of Service program are subject to change.
- B. Changes to the Drugs in Scope
 - 1. If currently available infused specialty medications are added to the Site of Service program medication list, prescribers will receive advanced notification per the terms of the provider contract with Medica.

| HCPCS | Brand Name | Generic Name |
|-------|---------------|-----------------------------|
| J3262 | ACTEMRA | tocilizumab |
| J1931 | ALDURAZYME | laronidase |
| Q5121 | AVSOLA | infliximab-axxq |
| J0490 | BENLYSTA | belimumab |
| J0597 | BERINERT | C1 esterase inhibitor |
| J1556 | BIVIGAM | intravenous immune globulin |
| J1566 | CARIMUNE | intravenous immune globulin |
| J1786 | CEREZYME | imiglucerase |
| J0717 | CIMZIA | certolizumab pegol |
| J2786 | CINQAIR | reslizumab |
| J0598 | CINRYZE | C1 esterase inhibitor |
| J7318 | CRYSVITA | burosumab |
| J1743 | ELAPRASE | idursulfase |
| J3060 | ELELYSO | taliglucerase alfa |
| J3380 | ENTYVIO | vedolizumab |
| J1428 | EXONDYS 51 | eteplirsen |
| J0180 | FABRAZYME | agalsidase beta |
| J1744 | FIRAZYR | icatibant |
| J1572 | FLEBOGAMMA | intravenous immune globulin |
| J1569 | GAMMAGARD | intravenous immune globulin |
| J1566 | GAMMAGARD S/D | intravenous immune globulin |
| J1557 | GAMMAPLEX | intravenous immune globulin |
| J1561 | GAMUNEX | intravenous immune globulin |
| Q5103 | INFLECTRA | infliximab-dyyb |
| J1290 | KALBITOR | ecallantide |
| J2840 | KANUMA | sebelipase alfa |
| J2507 | KRYSTEXXA | pegloticase |
| J0202 | LEMTRADA | alemtuzumab |
| J0221 | LUMIZYME | alglucosidase alfa |
| J3397 | MEPSEVII | vestronidase alfa-vjvk |
| J1458 | NAGLAZYME | galsulfase |
| J2350 | OCREVUS | ocrelizumab |

| HCPCS | Brand Name | Generic Name |
|-------|--------------|-----------------------------------|
| J1568 | OCTAGAM | intravenous immune globulin |
| J0129 | ORENCIA | abatacept |
| J1459 | PRIVIGEN | intravenous immune globulin |
| J3490 | RADICAVA | edaravone |
| J1745 | REMICADE | infliximab |
| Q5104 | RENFLEXIS | Infliximab-abda |
| J0596 | RUCONEST | c1 esterase inhibitor recombinant |
| J1602 | SIMPONI ARIA | golimumab |
| J1300 | SOLIRIS | eculizumab |
| J3357 | STELARA | ustekinumab |
| J3590 | TROGARZO | ibalizumab-uiyk |
| J2323 | TYSABRI | natalizumab |
| J3590 | ULTOMIRIS | ravulizumab |
| J1322 | VIMIZIM | elosulfase alfa |
| J3385 | VPRIV | velaglucerase alfa |
| J2357 | XOLAIR | omalizumab |

V. Exceptions

- A. Exceptions to the Site of Service program requirements are reviewed through the prior authorization process and may be granted on a case-by-case basis based on medical necessity.
- B. The administration of the infusion and injectable therapy referenced in this policy in a hospital outpatient setting is not considered medically necessary unless the below criteria are met:
 1. Hospital outpatient administration of infusion or injectable therapy is considered medically necessary for up to a 60-90-day period for members beginning a new treatment OR initial review of continuation of therapy.
 2. An outpatient infusion or injectable therapy service in a hospital outpatient setting is considered medically necessary for the applicable validity period when any of the following are present:
 1. Potential changes in the member's clinical condition are such that immediate access to specific services of a hospital setting, having emergency resuscitation equipment and personnel, and inpatient admission or intensive care is necessary. For example, the member is at significant risk of sudden life-threatening changes in medical status based on clinical conditions including but not limited to:
 - a. Intolerable fluid overload, including impaired or unstable renal function, or



- b. History of anaphylaxis to prior infusion therapy with a related pharmacologic or biologic agent despite standard premedication, or
 - c. Acute mental status/cognitive changes or physical impairment AND no home caregiver available; or
 - d. Vascular access not stable; or
 - e. Documented clinical history of cardiopulmonary conditions that may cause an increased risk of severe adverse reactions (including but not limited to thromboembolism, hypotension, seizures, aseptic meningitis syndrome, anaphylaxis, acute respiratory distress, pulmonary edema, apnea and transfusion associated lung disease); or
 - f. The member does not have access to home infusion AND the nearest office based provider who can provide that service exceeds the travel distance to the currently-servicing hospital outpatient center.
- 2. Age less than 18 or greater than 64; or
 - 3. Home deemed unsafe environment for infusion (e.g., too many pets, esp. birds, aggressive dogs, etc.). The next requirement will be provider office. Requires written documentation; or
 - 4. Member reasoning (e.g., often members don't want children exposed to the medication, etc.). The next requirement will be provider office; or
 - 5. Financial impact to member is high in a setting other than hospital outpatient center – these are reviewed case by case basis only.